Top entities: Roche, World Health Organization, Matt Sause.

What category does this event fall under?

Business — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 09, 2026. Coverage continues to evolve.

Business regulatory approval

Roche Elecsys IGRA TB CE Mark

Q: When did this event occur?

First reported Jul 09, 2026; last updated Jul 09, 2026.

Q: What is the market impact?

General. The CE Mark approval strengthens Roche's diagnostics portfolio, potentially increasing revenue from TB testing.

Analysis based on 8 articles · First reported Jul 09, 2026 · Last updated Jul 09, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The CE Mark approval strengthens Roche's diagnostics portfolio, potentially increasing revenue from TB testing. It reinforces Roche's position in the infectious disease diagnostics market, with positive implications for its Diagnostics division.

Healthcare Diagnostics Pharmaceuticals

Event Summary

Roche announced on July 9, 2026 that its Elecsys IGRA TB test, a blood-based assay for detecting tuberculosis infection (latent TB), received the CE Mark. The test runs on Roche's automated cobas immunoassay systems, providing results in under 24 hours with 19 minutes processing time per patient. Clinical studies showed 91.12% positive percent agreement and 94.57% negative percent agreement versus standard methods, with 95.32% specificity in low-risk cohorts. The test aims to expand global access to TB infection testing and support WHO elimination targets.

Key Actions

80 Roche received CE Mark

Entities Involved

stock

Roche

Roche received CE Mark for its Elecsys IGRA TB test, expanding its diagnostics offering and potentially boosting sales in TB testing.

Importance 100.0 Sentiment 40.0

ngo

World Health Organization

The test supports WHO's End TB Strategy targets by improving access to TB infection diagnostics.

Importance 30.0 Sentiment 0.0

per

Matt Sause

As CEO of Roche, Matt Sause announced the CE Mark and highlighted the test's role in advancing TB elimination.

Importance 20.0 Sentiment 0.0

Relationships

Roche related ↔ Matt Sause

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard